Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2010 - 2025)
Rigel Pharmaceuticals' quarterly Other Non-Current Liabilities came in at $5.0 million in Q1 2025, down 87.49% year-on-year from $40.0 million in Q1 2024, and down 87.49% quarter-over-quarter from $40.0 million in Q4 2024.
Rigel Pharmaceuticals has reported Other Non-Current Liabilities for 16 years, with the latest figure at $5.0 million in Q1 2025.
- For the quarter ending Q1 2025, Other Non-Current Liabilities fell 87.49% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2025 stood at $5.0 million (down 87.49% YoY), and the FY2024 full-year result was $40.0 million, changed 0.09% from the prior year.
- Other Non-Current Liabilities for Q1 2025 stood at $5.0 million, down from $40.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $57.5 million in Q1 2021, with the low at $5.0 million in Q1 2025.
- Average Other Non-Current Liabilities over 5 years is $43.0 million, with a median of $42.1 million recorded in 2023.
- Year-over-year, Other Non-Current Liabilities soared 1050.66% in 2021 and sank 87.49% in 2025.
- Tracing RIGL's Other Non-Current Liabilities over 5 years: stood at $52.7 million in 2021, then fell by 19.84% to $42.3 million in 2022, then fell by 5.49% to $39.9 million in 2023, then increased by 0.09% to $40.0 million in 2024, then tumbled by 87.49% to $5.0 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $5.0 million (Q1 2025), $40.0 million (Q4 2024), and $40.0 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 39.98 Mn |
| Sep 30, 2024 | 39.98 Mn |
| Jun 30, 2024 | 39.98 Mn |
| Mar 31, 2024 | 39.98 Mn |
| Dec 31, 2023 | 39.94 Mn |
| Sep 30, 2023 | 38.76 Mn |
| Jun 30, 2023 | 40.98 Mn |
| Mar 31, 2023 | 42.07 Mn |
| Dec 31, 2022 | 42.26 Mn |
| Sep 30, 2022 | 48.71 Mn |
| Jun 30, 2022 | 46.89 Mn |
| Mar 31, 2022 | 53.20 Mn |
| Dec 31, 2021 | 52.73 Mn |
| Sep 30, 2021 | 54.37 Mn |
| Jun 30, 2021 | 48.23 Mn |
| Mar 31, 2021 | 57.53 Mn |
| Dec 31, 2020 | 5.05 Mn |
| Sep 30, 2020 | 5.00 Mn |
| Jun 30, 2020 | 5.00 Mn |
| Mar 31, 2020 | 5.00 Mn |
| Dec 31, 2019 | 5.10 Mn |
| Jun 30, 2018 | 38,000.00 |
| Mar 31, 2018 | 38,000.00 |
| Dec 31, 2017 | 38,000.00 |
| Sep 30, 2017 | 77,000.00 |
| Dec 31, 2016 | 2,000.00 |
| Sep 30, 2016 | 8,000.00 |
| Jun 30, 2016 | 15,000.00 |
| Mar 31, 2016 | 21,000.00 |
| Dec 31, 2015 | 27,000.00 |
| Sep 30, 2015 | 33,000.00 |
| Jun 30, 2015 | 39,000.00 |
| Mar 31, 2015 | 46,000.00 |
| Dec 31, 2014 | 51,000.00 |
| Sep 30, 2014 | 57,000.00 |
| Jun 30, 2014 | 63,000.00 |
| Mar 31, 2014 | 69,000.00 |
| Dec 31, 2013 | 74,000.00 |
| Sep 30, 2013 | 80,000.00 |
| Jun 30, 2013 | 85,000.00 |
| Mar 31, 2013 | 91,000.00 |
| Dec 31, 2012 | 96,000.00 |
| Sep 30, 2012 | 102,000.00 |
| Jun 30, 2012 | 107,000.00 |
| Mar 31, 2012 | 112,000.00 |
| Dec 31, 2011 | 117,000.00 |
| Sep 30, 2011 | 123,000.00 |
| Jun 30, 2011 | 128,000.00 |
| Dec 31, 2010 | 137,000.00 |